Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Merus Labs International in a research report issued on Thursday, March 27th. HC Wainwright analyst A. He forecasts that the specialty pharmaceutical company will earn ($0.13) per share for the year.
Merus Labs International Stock Performance
Merus Labs International has a 1-year low of C$0.95 and a 1-year high of C$1.76. The firm has a 50 day moving average price of C$1.65.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Read More
- Five stocks we like better than Merus Labs International
- What Are Dividend Challengers?
- Ibotta Stock: Why the Buyback Looks Like a Bullish Bet
- 3 Warren Buffett Stocks to Buy Now
- Joby Aviation Stock: Analyst Confidence and Smart Money Align
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Momentum Stocks Near 52-Week Highs to Watch for More Growth
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
